Given the stage MSB is at the burn rate is reasonable. They have one product on the market in Japan and about to get FDA approval, and two with a reasonable chance of success late in phase 3. Even if both the phase 3 trials bomb, the GVHD treatment would support the current MC. The recent SP drop has knocked a lot of the premium out of the price and the risk to reward ratio looks good if you have a 12 to 24 month investment horizon. There is also the potential of a takeover or large partnership to act as positive surprise.
There is of course lots of risk (nothing in biotech is low risk), but as smallish part of a portfolio MSB looks attractive. This is why I have bought in and as you know I am highly skeptical of the sector as a whole.
Mesoblast - takeover target?, page-43
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |